Day: June 21, 2022

Zoom Apps SDK enables developers to build new applications that transform the meeting experience

SAN JOSE, Calif., June 21, 2022 (GLOBE NEWSWIRE) — Today, Zoom Video Communications, Inc. (NASDAQ: ZM) announced the general availability of the Zoom Apps SDK, which provides developers with the resources and support infrastructure needed to build Zoom Apps within the Zoom client. By building on the Zoom Apps SDK, developers can reach Zoom customers, and users can discover and add new apps within the same client they use every day. Over 100 Zoom Apps have been published by developer partners to enrich meeting experiences ranging from meeting productivity, team collaboration, and social networking to gaming.

“To meet customer expectations, organizations continue to look for ways to evolve their businesses and scale workflows, which leads to an increased need for developers to have access to develop innovative app capabilities and features,” said Brendan Ittelson, Chief Technology Officer at Zoom. “With the launch of the Zoom Apps SDK, the Zoom Developer Platform continues to expand and offer developers new ways to incorporate video communications and collaboration into their creations, transforming business workflows forever.”

“The ability to leverage APIs to enable application integration and innovation is a critical digital transformation need,” says Irwin Lazar, President and Principal Analyst at Metrigy. “More than 84% of IT professionals in our research say that API availability is important for employee and customer engagement use cases. General availability of the Zoom Apps SDK will make it easier, and faster, for developers to deliver business benefits through a variety of ways.”

Zoom Apps SDK broadens developer capabilities by:

• Increasing the reach of new applications by tapping into Zoom’s global and diverse audience, listing apps on the Zoom App Marketplace and in the Zoom client where apps can be installed even during a Zoom Meeting
• Extending new apps to create collaborative experiences across Zoom Meetings
• Creating engaging experiences for customers both within and outside of Zoom Meetings

Zoom Apps SDK is a JavaScript SDK that provides access to client features such as setting the Virtual Background while also providing the app context for the interaction. Fundamentally, it uses a method to get the meeting context, with identifiers for the user and meeting. These identifiers can be used with a comprehensive set of API endpoints from the Zoom Developer Platform, including REST APIs and Webhooks to enrich the app experience.

With the Zoom Apps SDK, companies are able to create engaging experiences within Zoom Meetings, and in the Zoom desktop window for asynchronous collaboration.

“In this new era of hybrid work, businesses are using more apps than ever to collaborate and get work done from anywhere,” said Ketan Kittur, Vice President, Product Management at Box. “We know that customers want all of their favorite apps to work securely and seamlessly together. With the Zoom Apps SDK, we created the Box app for Zoom which empowers our thousands of joint customers to work frictionlessly across our two platforms.”

Getting Started with Zoom Apps SDK
Building with Zoom Apps SDK is simple. Here’s how to get started:

1. Build the app: Utilize the Zoom Apps SDK to develop and customize an app.
2. Complete the submission checklist: Before submitting an app for review, ensure all items are completed in the Submission Requirements. The checklist covers marketing, privacy, legal, support, and technical information.
3. Submit the app for review: All apps submitted for publication undergo a thorough review, including functional and usability testing, and security and compliance review.
4. Publish on App Marketplace: Once published, the app will be available to all users through an embeddable button.

To learn more about the Zoom Apps SDK, please read our blog.

About Zoom
Zoom is for you. Zoom is a space where you can connect to others, share ideas, make plans, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for large enterprises, small businesses, and individuals alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Public Relations
Kim Gaertner
Developer PR Manager
press@zoom.us

FedEx makes a strategic investment in FourKites, which FourKites will leverage to develop FourKites X to help transform global supply chains with volumes of data insights from both companies’ networks

FourKites’ real-time visibility platform has integrated intelligence at every point of the supply chain, and currently supports 2.5 million shipments a day, connecting the supply chains of 50% of Fortune 500 companies. Through this collaboration, FourKites will be using its machine learning and artificial intelligence capabilities with data insights from the FedEx network – which reaches more than 220 countries and territories, linking more than 99 percent of the world’s GDP, through more than 16.5 million shipments daily – to create a new end-to-end supply chain intelligence platform called FourKites X. FourKites X will provide tools and insights to help large shippers and logistics providers mitigate the impacts of sustained challenges via a suite of offerings ranging from dynamic planning and pre-shipment, to enhanced visibility and proactive alerts, to supply chain optimization insights.

To support this alliance and the launch of FourKites X, FedEx has made a strategic investment in FourKites.

“This is an exciting collaboration between two industry leaders and innovators coming together to unlock new opportunities for our customers,” said Sriram Krishnasamy, CEO, FedEx Dataworks. “If the last two years have taught us anything, it’s that companies need to work together in order to work smarter and faster. Our collaboration with FourKites creates a data ecosystem that will deliver a new level of predictability and visibility to help businesses build smarter supply chains in today’s unpredictable and complex business environment.”

“We are excited to announce this groundbreaking platform and strategic collaboration with FedEx,” said Mathew Elenjickal, FourKites Founder & CEO. “Our organizations share an unwavering commitment to customer success through strategic innovation. Together, we are working to pave the future of global supply chains, built on a foundation of data and machine learning to deliver new value to those global supply chains.”

FourKites X – A Complete Picture of Global Supply Chain Operations

FedEx Dataworks, a business unit in FedEx focused on making supply chains smarter through a powerful data science approach and machine learning capabilities, will support FourKites’ development of the new platform, FourKites X, that will help give customers deeper actionable insights, more accurate ETAs, and more intelligent supply chains to reduce supply chain volatility, and improve top-line growth.

The platform is being designed to help large shippers and logistics providers identify areas of opportunity, such as:

• How chief supply chain officers can improve planning to address empty shelves and manufacturing slowdowns
• How companies can use data to turn supply chain crises into chances to improve the customer experience
• How chief financial officers can optimize supply chains for growth and efficiency

“When it comes to supply chain data, more is always better,” said Steve Banker, Vice President, Supply Chain Services, at ARC Advisory Group. “The collaboration between FourKites and FedEx is exceptional in both the volume of data that it will aggregate, and in the degree to which it could improve predicted times of arrival, planning, and more. FourKites X can be a big step forward for this market.”

Customers of FourKites X will be able to integrate the platform with existing systems, and they will be able to receive new capabilities in a modular way with support from data engineers, data scientists and user experience experts. The FourKites X solution will include pre-built applications and an intuitive dashboard, which will allow customers to unlock things like pre-shipment weather advisories and supply chain insights.

To learn more about FourKites X, click here.

About FedEx Corp.
FedEx Corp. (NYSE: FDX) provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce, and business services. With annual revenue of $92 billion, the company offers integrated business solutions through operating companies competing collectively, operating collaboratively, and innovating digitally under the respected FedEx brand. Consistently ranked among the world’s most admired and trusted employers, FedEx inspires its nearly 550,000 employees to remain focused on safety, the highest ethical and professional standards, and the needs of their customers and communities. FedEx is committed to connecting people and possibilities around the world responsibly and resourcefully, with a goal to achieve carbon-neutral operations by 2040. To learn more, please visit fedex.com/about.

About FourKites^®
Leading global supply chain visibility platform FourKites^® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,000 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit www.fourkites.com.

Media Contacts
Marianna Vyridi
Big Valley Marketing for FourKites
(650) 468-3263
mvyridi@bigvalley.co

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/957af2bd-51a9-4e5f-8837-680cc2e823ea

Neeyamo is pleased to share the announcement of Catherine Honey, who will aid the company in accelerating its partnership and growth strategy.

Speaking about Catherine Honey’s arrival, Vivek Khanna, President and Chief Client Partner, said, “We are delighted to welcome Catherine to Neeyamo’s family. Her responsibilities will include strengthening our relationships with our partners and assisting in developing programs to onboard various system integrators, accelerating Neeyamo’s growth by expanding its presence in new geographies, and contributing to the company’s revenue through significant channels. Given her proven track record and remarkable experience in the industry, I am certain that she is an ideal leader to head Neeyamo’s global alliances team.”

Catherine Honey said, “I am thrilled to join Neeyamo, a company I’ve been following closely. I am also familiar with the industry and business structure. The energy I see across all its locations and workforce levels have been amazing. I look forward to expanding Neeyamo’s global alliance network and propelling the company to new heights.”

Catherine Honey previously worked at Safeguard Global as Vice President, Solutions Consulting and HCM Ecosystem Alliances, overseeing the solutions consulting business, prior to which she served as the company’s VP of Strategic Partner Relations. She was responsible for managing key partnerships and driving alliance activities, identifying, and evaluating new partnership opportunities, developing partnership approaches, and building relationships to deliver added value. She was also in charge of increasing Safeguard Global’s market presence and raising industry knowledge of the company’s products and services for enterprises expanding and operating globally.

Catherine has over 30 years of expertise in human capital management, having worked as a practitioner, service provider, and consultant for companies such as EY, Mercer Consulting, and Fidelity Investments. She has lived and worked around the world, is a veteran of two expatriate assignments, and is a published author and frequent speaker on global strategy, service delivery, and operations. In addition, she is active in several professional organizations and is a member of APA’s National Speakers Bureau. Catherine holds a BA from Temple University and an MBA from Bentley University.

About Neeyamo

Neeyamo is a leading technology-enabled global payroll and EOR solutions provider for multinational and micro-multinational corporations worldwide. With an extensive team of professionals serving clients across 190+ countries, Neeyamo leverages its unique service-based model and functionality-rich, next-generation HR & payroll product portfolio to help organizations enable agile and scalable business. To know more, visit www.neeyamo.com.

Media contact: corporate.communications@neeyamo.com

Related Images

Image 1: Catherine A. Honey

Catherine Honey appointed as Neeyamo’s Head of Global Alliances

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Catherine A. Honey

Investors Back Groundbreaking AgTech Startup that Programs Plants with Light

NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) — BioLumic Inc. (“BioLumic”) today announced the closing of a $13.5-million Series B funding round that will be used to accelerate commercial growth for its cutting-edge, patented agricultural technology that harnesses the power of ultraviolet light to improve plant productivity.

The funding round is led by OurCrowd and is joined by Finistere Ventures, Icehouse Ventures, Rabo Ventures, Entourage Effect Capital, Arcview Ventures Seed Fund, Flatiron Venture Partners, RIV Capital, Virtu Capital, Bravos Capital, Privthi, NZ Booster Fund, Norwind Capital, MIG Nominee No 1 Limited, Aspire NZ Seed Fund and others.

“OurCrowd is proud to be leading this important investment round for BioLumic,” says OurCrowd CEO Jon Medved. “Now, just when a hungry world is perched on the edge of a food crisis, BioLumic is bringing the photonics revolution to agriculture with its stunning signaling platform which literally programs plants with light. This is a company whose time has come.”

BioLumic’s Light Signal Recipe™ platform uses proprietary knowledge of how UV light influences plant biology and genetics, data science, and patented treatment technology. Without adding chemicals or genetic engineering, the BioLumic platform empowers agricultural, horticultural and cannabis growers to improve overall plant health, quality and yield.

“BioLumic is applying light in an entirely new way to meet the challenge of improving crop growth, plant yield and quality without increasing energy consumption,” says BioLumic CEO Steve Sibulkin. “Light Signal Recipes are clean, scalable and available at a fraction of the time, risk and cost of traditional solutions. Moving forward with this great group of savvy investors speeds our ability to bring these important outcomes to customers.”

BioLumic will use the funds from this latest financing round to market its technology, focusing specifically on cannabis, soybean, corn, canola and strawberry. With cannabis, BioLumic plans to deepen relationships with cultivation leaders and technology partners, while adding to a growing library of Light Signal Recipes that have already triggered large, combined gains in dry flower yield, THC concentration, minor cannabinoids and terpenes. Funding will also be used to advance a new generation of Light Signal Recipes focused on photosynthetic and nutrient use efficiency.

About BioLumic — BioLumic is an agricultural technology company founded in 2013. The company’s Light Signal Platform and proprietary UV treatment systems improve the performance of key plant traits using short-duration UV treatments for both seedlings and seeds. These treatments provide the plants with several important and long-term benefits, including improved crop consistency, increased yield and stronger disease resistance. BioLumic has offices in the United States and New Zealand. To learn more, visit www.biolumic.com.

Contact – Steve Sibulkin, CEO, +1 917 502 4400

Australian biotech Skin2Neuron Pty Ltd. (S2N) has what no one has to date – reversal of a dementia-like syndrome in a natural animal form of Alzheimer’s disease.

In a world first, a veterinary trial led by S2N suggests the audacious concept may work. S2N’s new form of cell therapy reversed the dementia-like syndrome that strikes down many older pet dogs with Alzheimer’s.

Co-founder Professor Michael Valenzuela explains, “Because of deep parallels between the canine brain and human brain, and canine Alzheimer’s and human Alzheimer’s, I started this trial 10 years ago with the assumption that if it’s going to work in humans, then it needs to work in dogs first. And the results exceeded my wildest expectations.”

Dementia was reversed in more than half of the canine patients, with a clinically meaningful improvement in 80%. For many of the carers, it was a life-changing turnaround, some at the point of considering euthanasia before treatment.

Fiona Gibbs, carer of Leo, a 12-yo Pomeranian in the trial, describes the impact: “Before treatment, Leo was really bad, forgetting who we were, getting lost, and having these unpredictable episodes where he would growl and snap – it was really scary and we just couldn’t go on. A few months after treatment, he started getting better, and then he was back to his normal self, and we look back at the movies and think, ‘Wow, was he really that bad?’”

Leo’s life-changing improvement lasted almost two years, typical of clinical recovery in the trial.

And when Valenzuela looked in the brain, the findings were remarkable, “The hippocampus, the memory centre of the brain, was packed with baby neurons and new synapses, precisely where we delivered the cells. Compared to untreated dogs, it was like night and day”.

Importantly, microscopic analysis confirmed the dogs had classic Alzheimer pathology. In other words, the cell therapy worked in the setting of natural disease, a first of its kind.

“Given our doggie patients also had many of the same health issues that older people face, it gives me even greater confidence,” says Valenzuela.

Stem cell pioneer Professor Brent Reynolds of the University of Florida, not connected to the study, considers it a landmark in the quest to treat brain degeneration. “Alzheimer’s is an area of medicine that needs new thinking. What stands out are clinically meaningful outcomes in a natural canine model of this devastating disease. Also, the company’s approach to generating cells from the same patient could solve many of the problems facing cell therapies.”

The study helps pave the way for S2N to launch a world-first human trial in 2024.

Contact

Professor Michael Valenzuela

Co-founder & CEO, Skin2Neuron Pty Ltd.

mvalenzuela@skin2neuron.org

+61 413 603 784 (AEST)

Related Images

Image 1: Figure 1/2

Hippocampus (memory centre) of an older dog with dementia-like syndrome successfully treated with S2N’s cells. It is packed with green cells that are new neurons (brain cells) and yellow dots, new synapses (connections between brain cells).

Image 2: Figure 2/2

Same brain area in an aged untreated dog. There are no new neurons (no green cells), a few red dots (old synapses), but no new synapses (no yellow dots).

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Figure 1/2

June 21, 2022

• Prestigious title awarded for the team’s multi-disciplinary and human-centered approach to designing solutions that improve people’s lives
• Celebratory event accompanied by presentation of awards for Philips’ three Red Dot Design ‘Best of the Best’ product ratings

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company’s Experience Design Team has been awarded the honorary title of ‘Red Dot: Design Team of the Year 2022’. The Red Dot design organization awarded the title in recognition of the Philips Experience Design Team’s multidisciplinary approach to creating integrated solutions that address major challenges in healthcare, such as ageing populations, the increase in chronic illnesses, the COVID-19 pandemic, and escalating healthcare costs, together with its strong focus on the user and patient experience.

On behalf of the team, Philips’ Chief Design Officer Sean Carney was presented the award during the Red Dot award ceremony that took place on the evening of Monday, June 20 in Essen, Germany. It is the first time in the history of the Red Dot Design Award (1988) that this award has been bestowed on a design team for the second time.

Philips’ Experience Design Team comprises a multidisciplinary team of designers operating out of 13 design centers across North and South America, Europe and Asia. Applying deep human insights and cutting-edge technologies, the team helps to create healthcare products and services that truly improve lives, making it a key part of Philips’ mission to improve the lives of 2.5 billion people a year by 2030, including 400 million in underserved communities.

“Philips’ design team has achieved what many wish for, but few manage – holistic solutions that require the interplay of technology and design to make a lasting positive impact on the progress of their own company and the transformation of healthcare,” said Professor Dr. Peter Zec, founder and CEO of Red Dot. “The multidisciplinary Philips Experience Design Team has been proving for years that it is a leader in the field of healthcare technology. The Red Dot: Design Team of the Year 2022 award is a well-deserved recognition of their work.”

“For more than a decade we’ve recognized that integrated systems combining smart devices, systems, software, and services with real-time data and patient histories are the only way to deliver on the quadruple aim of better patient outcomes, enhanced patient and staff experiences, and lower cost of care, and do it across the entire patient journey,” said Sean Carney, Chief Design Officer at Philips. “I am immensely proud that my team has been awarded the prestigious title of Red Dot: Design Team of the Year in recognition of the outstanding healthcare solutions they are helping deliver.”

In April, Philips received three Red Dot Design ‘Best of the Best’ awards for ground-breaking design excellence, bringing the company’s cumulative ‘Best of the Best’ total over the years to 27, next to more than 460 Red Dot awards in total.

Selected independently
Red Dot design awards are awarded for submitted products that are judged by the Red Dot jury to be outstanding in terms of their aesthetic appeal, functionality, smartness or innovation. The Red Dot: Design Team of the Year is selected independently from design teams with a consistent track record of innovative, top-class design achievements.

Learn from Philips Experience Design team member Hyelin Lee what it means to put human-centered and sustainable circular-ready design front-and-center in the end-to-end design process.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips Ingenia MR
• Philips Lumify portable ultrasound
• Philips Chief Design Officer Sean Carney receives the Red Dot Design Team of the Year 2022 award

This is the new fantasy creature from the Phantasticals campaign that Ferrer has relaunched, coinciding with Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, on June 21. The aim is to raise public awareness of this rare, neurodegenerative, progressive disease that affects the motor neurons in the brain. Ferrer is leading the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug FNP122 in the treatment of ALS.

BARCELONA, Spain, June 21, 2022 (GLOBE NEWSWIRE) — On Global Amyotrophic Lateral Sclerosis / Motor Neuron Disease (ALS/MND) Awareness Day on June 21, the Phantasticals campaign, run by Ferrer, the pharmaceutical company, has added a new fantasy creature, with the aim of raising awareness of ALS, a rare, neurodegenerative, progressive disease that affects the motor neurons in the brain.

The new character, a dragon called ALSton, joins the first creatures that Ferrer unveiled for World Pulmonary Hypertension (PH) Day on May 5: the mermaids PHoebe, PAHola and PHILipa, three mythological beings that help to explain Pulmonary Hypertension (PH) and two of its subtypes: Pulmonary Arterial Hypertension and Pulmonary Hypertension due to Interstitial Lung Disease (PAH and PH-ILD).

In this campaign, the Phantasticals are rare fantasy creatures that are extraordinary, unique and, of course, fantastic. Along with the characteristics that make them so special, they all have something in common: they are strong, resilient, and often go unnoticed. Just like people who live with rare, serious and debilitating diseases, such as pulmonary hypertension and amyotrophic lateral sclerosis.

As Oscar Pérez, Ferrer’s Chief Marketing, Market Access and Business Development Officer, points out, “the Phantasticals campaign is aligned with Ferrer’s purpose of making a positive impact in society, giving visibility to a series of pathologies about which there is a great deal of ignorance and little public awareness of its effects. After raising awareness about pulmonary hypertension and offering our support to people living with the disease, we are now focusing on ALS, a disease in which we are also working to provide solutions through pharmaceutical research.”

At www.phantasticals.com, the Phantasticals explain the main aspects of the different pathologies, emphasizing their low prevalence, symptoms, diagnosis and possible treatments.
Engagement Beyond Awareness: ADORE Clinical Trial

Yet another example of Ferrer’s commitment to people living with ALS is the ADORE Phase III clinical trial to evaluate the safety and efficacy of the investigational drug, FNP122, in the treatment of ELA.

The study, which is currently in the recruitment phase, is an international, multicenter, randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned to receive FNP122 or a placebo in a 2:1 ratio. FNP122 is an oral formulation of edaravone, a compound that can prevent oxidative stress at the cellular level.

For more information: https://www.ferrer.com/en/adore-clinical-trial
Press contact details:

gortizdez@ferrer.com
+34 936 003 779

Related Images

Image 1: Phantasticals awareness campaign

The new phase of the Phantasticals campaign introduces ALSton the dragon to raise awareness on amyotrophic lateral sclerosis.

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Phantasticals awareness campaign